High on-treatment platelet reactivity with ticagrelor versus prasugrel: a systematic review and meta-analysis

被引：50
作者：
Lemesle, G. [1 ,2 ,3 ]
Schurtz, G. [1 ]
Bauters, C. [1 ,2 ,3 ]
Hamon, M. [4 ,5 ]
机构：
[1] CHRU Lille, F-59037 Lille, France
[2] Inst Pasteur, Inserm U744, F-59019 Lille, France
[3] Univ Lille, Fac Med, Lille, France
[4] Ctr Hosp Univ Caen, Caen, France
[5] Fac Med Caen, Caen, France
来源：
JOURNAL OF THROMBOSIS AND HAEMOSTASIS | 2015年 / 13卷 / 06期
关键词：
acute coronary syndrome; antiplatelet agents; coronary artery disease; percutaneous coronary intervention; platelet function tests; ACUTE CORONARY SYNDROME; ASPIRIN-TREATED PATIENTS; MYOCARDIAL-INFARCTION; RANDOMIZED ASSESSMENT; DOSE CLOPIDOGREL; ACHIEVES GREATER; INHIBITION; INTERVENTION; EVENTS; IMPACT;
D O I：
10.1111/jth.12907
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
BackgroundTicagrelor and prasugrel have shown superiority over clopidogrel. However, it remains unclear if one is superior to another regarding on-treatment platelet reactivity. ObjectivesTo compare the impact of ticagrelor and prasugrel on high on-treatment platelet reactivity (HTPR). MethodsThe PubMed and Cochrane databases were searched for eligible studies in December 2014. Studies were eligible if they compared ticagrelor and prasugrel regarding high on-treatment platelet reactivity (HTPR). Pooled estimates were calculated by using a random-effects model with 95% confidence intervals. ResultsWe included 14 studies and 1822 patients: 805 and 1017 in the ticagrelor and prasugrel groups, respectively. The rate of HTPR was significantly lower in the ticagrelor group: 1.5% vs. 9.8% (RR=0.27 [0.14-0.50]). The pre-specified analysis focusing on randomized trials (n=10) showed consistent results (RR=0.27 [0.12-0.60]). ConclusionOur results suggest that ticagrelor allows a higher platelet reactivity inhibition as compared with prasugrel and leads to a further decrease in the rate of HTPR.
引用
收藏
页码：931 / 942
页数：12
相关论文
共 42 条
  • [1] Ticagrelor vs prasugrel one-month maintenance therapy: Impact on platelet reactivity and bleeding events
    Alexopoulos, Dimitrios
    Stavrou, Katerina
    Koniari, Ioanna
    Gkizas, Vassilios
    Perperis, Angelos
    Kontoprias, Kosmas
    Vogiatzi, Chrysoula
    Bampouri, Theodora
    Xanthopoulou, Ioanna
    [J]. THROMBOSIS AND HAEMOSTASIS, 2014, 112 (03) : 551 - 557
  • [2] Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients With Diabetes
    Alexopoulos, Dimitrios
    Xanthopoulou, Ioanna
    Mavronasiou, Eleni
    Stavrou, Katerina
    Siapika, Argyro
    Tsoni, Evropi
    Davlouros, Periklis
    [J]. DIABETES CARE, 2013, 36 (08) : 2211 - 2216
  • [3] Randomized Assessment of Ticagrelor Versus Prasugrel Antiplatelet Effects in Patients with ST-Segment-Elevation Myocardial Infarction
    Alexopoulos, Dimitrios
    Xanthopoulou, Ioanna
    Gkizas, Vassilios
    Kassimis, George
    Theodoropoulos, Konstantinos C.
    Makris, George
    Koutsogiannis, Nikolaos
    Damelou, Anastasia
    Tsigkas, Grigorios
    Davlouros, Periklis
    Hahalis, George
    [J]. CIRCULATION-CARDIOVASCULAR INTERVENTIONS, 2012, 5 (06) : 797 - 804
  • [4] Ticagrelor Versus Prasugrel in Acute Coronary Syndrome Patients With High On-Clopidogrel Platelet Reactivity Following Percutaneous Coronary Intervention A Pharmacodynamic Study
    Alexopoulos, Dimitrios
    Galati, Anastasia
    Xanthopoulou, Ioanna
    Mavronasiou, Eleni
    Kassimis, George
    Theodoropoulos, Konstantinos C.
    Makris, George
    Damelou, Anastasia
    Tsigkas, Grigorios
    Hahalis, George
    Davlouros, Periklis
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2012, 60 (03) : 193 - 199
  • [5] Pharmacodynamic Evaluation of Switching From Ticagrelor to Prasugrel in Patients With Stable Coronary Artery Disease Results of the SWAP-2 Study (Switching Anti Platelet-2)
    Angiolillo, Dominick J.
    Curzen, Nicholas
    Gurbel, Paul
    Vaitkus, Paul
    Lipkin, Fred
    Li, Wei
    Jakubowski, Joseph A.
    Zettler, Marjorie
    Effron, Mark B.
    Trenk, Dietmar
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (15) : 1500 - 1509
  • [6] A pharmacodynamic comparison of prasugrel vs. high-dose clopidogrel in patients with type 2 diabetes mellitus and coronary artery disease: results of the Optimizing anti-Platelet Therapy In diabetes MellitUS (OPTIMUS)-3 Trial
    Angiolillo, Dominick J.
    JoseBadimon, Juan
    Saucedo, Jorge F.
    Frelinger, Andrew L.
    Michelson, Alan D.
    Jakubowski, Joseph A.
    Zhu, Baojin
    Ojeh, Clement K.
    Baker, Brian A.
    Effron, Mark B.
    [J]. EUROPEAN HEART JOURNAL, 2011, 32 (07) : 838 - 846
  • [7] [Anonymous], PLATELETS
  • [8] Effectiveness of switching 'low responders' to prasugrel to ticagrelor after acute coronary syndrome
    Bassez, Clemence
    Deharo, Pierre
    Pankert, Mathieu
    Bonnet, Guillaume
    Quilici, Jacques
    Lambert, Marc
    Verdier, Valentine
    Morange, Pierre
    Alessi, Marie-Christine
    Bonnet, Jean-Louis
    Cuisset, Thomas
    [J]. INTERNATIONAL JOURNAL OF CARDIOLOGY, 2014, 176 (03) : 1181 - 1182
  • [9] Relationship between post-treatment platelet reactivity and ischemic and bleeding events at 1-year follow-up in patients receiving prasugrel
    Bonello, L.
    Mancini, J.
    Pansieri, M.
    Maillard, L.
    Rossi, P.
    Collet, F.
    Jouve, B.
    Wittenberg, O.
    Laine, M.
    Michelet, P.
    Bessereau, J.
    Lemesle, G.
    Dignat-George, F.
    Paganelli, F.
    Camoin-Jau, L.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2012, 10 (10) : 1999 - 2005
  • [10] Ticagrelor Increases Adenosine Plasma Concentration in Patients With an Acute Coronary Syndrome
    Bonello, Laurent
    Laine, Marc
    Kipson, Nathalie
    Mancini, Julien
    Helal, Olfa
    Fromonot, Julien
    Gariboldi, Vlad
    Condo, Jocelyne
    Thuny, Franck
    Frere, Corinne
    Camoin-Jau, Laurence
    Paganelli, Franck
    Dignat-George, Francoise
    Guieu, Regis
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (09) : 872 - 877
12345